Dewey McLin

Dr. McLin brings over 15 years of Medical Affairs experience establishing and scaling Medical Affairs functions and teams through all stages of clinical development from the research stage through commercialization. Most recently Dr. McLin served as Vice President, Medical Affairs at Sesen Bio. Prior to joining Sesen, he served as Sr. Director of Medical Affairs and Product Development Team lead for Medical Affairs at Greenwich Biosciences, where he played an important role in the complex, successful commercialization of the first cannabis-based drug approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of refractory epilepsy. During his career, he has supported the launch of six products at start-up and mid-size pharmaceutical companies, where he has identified innovative, data-driven opportunities to engage patients, prescribers, advocacy groups, and payers. Dr. McLin received his bachelor’s degree from Indiana University and his Doctorate in Biological Sciences from the University of California, Irvine.